ESMO 2024: T-DXd Yields Significant Intracranial Response in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
Twelve-month progression-free survival was 61.6% among patients with stable and active brain metastases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.